Literature DB >> 15879006

Resistance of human astrocytoma cells to apoptosis induced by mitochondria-damaging agents: possible implications for anticancer therapy.

Stefania Ceruti1, Alessia Mazzola, Maria P Abbracchio.   

Abstract

The success of anticancer chemotherapy is often hampered by resistance to apoptosis, which may depend on defects in intracellular cell death pathways. Characterizing the alterations of these pathways is a prerequisite for developing alternative and effective antitumoral strategies. Here, we investigated the susceptibility of a human astrocytoma cell line, ADF, to apoptotic cell death induced by mitochondria-damaging agents. Neither the anticancer agent betulinic acid nor the "mitochondriotropic" poisons 2-deoxy-d-ribose and potassium cyanide induced apoptosis of these cells, despite induction of highly significant mitochondrial depolarization, eventually resulting in necrotic death. Resistance to apoptosis was not due to presence of the multidrug resistance pump or to impaired expression of caspase-8, caspase-9, or "executioner" caspase-3. Cloning of caspase-9 revealed the presence of full-length caspase-9alpha and a short variant (caspase-9beta), which, in other tumors, acts as a dominant negative of the long isoform. All analyzed clones showed a point mutation in the prodomain region that is known to interact with mitochondria-released factors. Thus, in these human astrocytoma cells, mitochondria-damaging agents induce a regulated form of mitochondrial-dependent necrotic cell death (oncosis). Resistance to apoptosis is due to an intrinsic defect of caspase-9, leading to inhibition of enzyme activation and/or impaired interaction with proteins released from depolarized mitochondria. These results may have implications for developing strategies aimed at overcoming tumor resistance to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879006     DOI: 10.1124/jpet.105.085340

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation.

Authors:  Céline Bruyère; Sébastien Madonna; Gwendoline Van Goietsenoven; Véronique Mathieu; Jean Dessolin; Jean-Louis Kraus; Florence Lefranc; Robert Kiss
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

3.  Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Authors:  D Amendola; M De Salvo; R Marchese; C Verga Falzacappa; A Stigliano; E Carico; E Brunetti; M Moscarini; B Bucci
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

4.  Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population.

Authors:  Inês Marques; Ana L Teixeira; Marta Ferreira; Joana Assis; Francisco Lobo; Joaquina Maurício; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2013-05-05       Impact factor: 2.316

Review 5.  Metabolic management of microenvironment acidity in glioblastoma.

Authors:  Thomas N Seyfried; Gabriel Arismendi-Morillo; Giulio Zuccoli; Derek C Lee; Tomas Duraj; Ahmed M Elsakka; Joseph C Maroon; Purna Mukherjee; Linh Ta; Laura Shelton; Dominic D'Agostino; Michael Kiebish; Christos Chinopoulos
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

6.  Opposite effects of uracil and adenine nucleotides on the survival of murine cardiomyocytes.

Authors:  Alessia Mazzola; Emanuela Amoruso; Elena Beltrami; Davide Lecca; Silvia Ferrario; Simona Cosentino; Elena Tremoli; Stefania Ceruti; Maria P Abbracchio
Journal:  J Cell Mol Med       Date:  2008-04       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.